AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11472705 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg)
Number of subjects: 3916
Study 9926538 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation Therapy (TSF)
Number of subjects: 806
Study 9926538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) involvement
Number of subjects: 806
Study 9926538 — intervention group
Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 806
Study 9926538 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Coping Skills Therapy (CBT)
Number of subjects: 806
Study 7831650 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparin 4000 anti-Xa units once a day subcutaneously for 3 months
Number of subjects: 187
Study 7831650 — intervention group
Group type: COMPARATOR
Intervention: Warfarin treatment for 3 months
Number of subjects: 187
Study 7831650 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (enoxaparin) during 9-month follow-up
Number of subjects: 187
Study 7831650 — intervention group
Group type: COMPARATOR
Intervention: Warfarin during 9-month follow-up
Number of subjects: 187
Study 7831650 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH after one year
Number of subjects: 187
Study 7831650 — intervention group
Group type: COMPARATOR
Intervention: Warfarin after one year
Number of subjects: 187
Study 2978782 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Mississippi dental care system (automatic toothbrushing device)
Number of subjects: 0
Study 2978782 — intervention group
Group type: COMPARATOR
Intervention: Routine (ordinary, manual) regimens of oral hygiene
Number of subjects: 0
Study 7007588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroid regimen
Number of subjects: 131
Study 7007588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose steroid regimen
Number of subjects: 131
Study 7007588 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids alone
Number of subjects: 131
Study 7007588 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids supplemented with cimetidine
Number of subjects: 131
Study 7007588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-dose heparin
Number of subjects: 131
Study 7007588 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose heparin
Number of subjects: 131
Study 28810394 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face behavioral weight loss
Number of subjects: 52
Study 28810394 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based behavioral weight loss
Number of subjects: 52
Study 28810394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid (web plus optional community sessions)
Number of subjects: 52
Study 28683763 — intervention group
Group type: EXPERIMENTAL
Intervention: PSN
Number of subjects: 14
Study 28683763 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 14
Study 28683763 — intervention group
Group type: COMPARATOR
Intervention: PSP
Number of subjects: 14
Study 26514759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial hypertension patients
Number of subjects: 65
Study 26514759 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study 22404253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam
Number of subjects: 72
Study 22404253 — intervention group
Group type: COMPARATOR
Intervention: Control (cotton rolls)
Number of subjects: 72
Study 23024440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 × 8 mg/d (dex-early)
Number of subjects: 21
Study 23024440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone started on day 2 at 4,559 m (dex-late)
Number of subjects: 21
Study 23024440 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study 19123142 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 0.5% eyedrops three times daily for 5 days
Number of subjects: 120
Study 19123142 — intervention group
Group type: COMPARATOR
Intervention: Classic dosage group (every 2 hours on days 1 and 2, then every 4 hours on days 3-5)
Number of subjects: 120
Study 17447828 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day during week 1, 300 mg/day during week 2, then 200, 300 or 400 mg/day based on efficacy and tolerability assessment.
Number of subjects: 266
Study 15044817 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA‐CHDF (polymethylmethacrylate membrane hemofilter)
Number of subjects: 25
Study 11813282 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 821
Study 11813282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 9701178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil-enriched sunflower oil (FO) margarine
Number of subjects: 47
Study 9701178 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SO) margarine
Number of subjects: 47
Study 7904002 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 302
Study 7904002 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 302
Study 2545054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (1500 aPTT U) combined with 0.5 mg dihydroergotamine (LMH/DHE)
Number of subjects: 201
Study 2545054 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (2500 IU) combined with 0.5 mg dihydroergotamine (H/DHE)
Number of subjects: 201
Study 790113 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate by inhalation (400 mug/day)
Number of subjects: 14
Study 790113 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone by mouth
Number of subjects: 14
Study 31270121 — intervention group
Group type: EXPERIMENTAL
Intervention: DentalVibe (DV) device
Number of subjects: 41
Study 28327450 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP (attenuated-signal plaque) observed pre-intervention
Number of subjects: 136
Study 28327450 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP score pre-intervention
Number of subjects: 136
Study 28327450 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP score during follow-up
Number of subjects: 136
Study 28327450 — intervention group
Group type: EXPERIMENTAL
Intervention: CP (calcified plaque) score during follow-up
Number of subjects: 136
Study 28327450 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP score decrease
Number of subjects: 136
Study 26267141 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Community Case Management (iCCM)
Number of subjects: 1036
Study 26267141 — intervention group
Group type: COMPARATOR
Intervention: Control (no iCCM)
Number of subjects: 1036
Study 22871378 — intervention group
Group type: EXPERIMENTAL
Intervention: Greening intervention (cleaning, planting grass and trees, building a wooden fence)
Number of subjects: 29
Study 22871378 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 29
Study 21913053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (300/100 mg once daily)
Number of subjects: 82
Study 21913053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 82
Study 20037643 — intervention group
Group type: EXPERIMENTAL
Intervention: ITN use
Number of subjects: 383
Study 20037643 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (42-80 months)
Number of subjects: 383
Study 20037643 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of ITN use and older age
Number of subjects: 383
Study 18172382 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention in Nanhua county (computers, training, ongoing support)
Number of subjects: 0
Study 18172382 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention in Mouding county (computers only)
Number of subjects: 0
Study 18172382 — intervention group
Group type: COMPARATOR
Intervention: Control group in Dayao county (no intervention)
Number of subjects: 0
Study 14743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (9 pairs)
Number of subjects: 26
Study 14743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (12 pairs)
Number of subjects: 26
Study 14743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (5 pairs)
Number of subjects: 26
Study 11502515 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of vancomycin (CIV)
Number of subjects: 119
Study 11502515 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusions of vancomycin (IIV)
Number of subjects: 119
Study 9509950 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of aspirin (ASA)
Number of subjects: 250
Study 9509950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 250
Study 7512101 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of terfenadine
Number of subjects: 12
Study 7512101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2975583 — intervention group
Group type: EXPERIMENTAL
Intervention: Depotmedroxyprogesterone acetate (Depoprovera) 150 mg every 84 +/- 7 days
Number of subjects: 400
Study 2975583 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone enanthate (Noristerat) 200 mg every 56 +/- 7 days
Number of subjects: 400
Study 31174831 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate 1 (S2/cre5/S15domV/rec1/hifi3)
Number of subjects: 30
Study 31174831 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate 2 (S2/S15domV/CpG40)
Number of subjects: 30
Study 31174831 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate 1
Number of subjects: 30
Study 31174831 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate 2
Number of subjects: 30
Study 29037984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (administered every 3-4 weeks for six doses, then every 3-6 months until the end of 5 years)
Number of subjects: 1739
Study 29037984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 1739
Study 29037984 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (standard adjuvant systemic therapy alone)
Number of subjects: 1739
Study 25149298 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic guidance (group 2)
Number of subjects: 70
Study 25149298 — intervention group
Group type: COMPARATOR
Intervention: Manual guidance (group 1)
Number of subjects: 70
Study 23515640 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 91
Study 23515640 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 21247520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid plus low-dose statin
Number of subjects: 1393
Study 21247520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid plus moderate-dose statin
Number of subjects: 1393
Study 21247520 — intervention group
Group type: COMPARATOR
Intervention: Low-dose statin monotherapy
Number of subjects: 1393
Study 21247520 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose statin monotherapy
Number of subjects: 1393
Study 21247520 — intervention group
Group type: COMPARATOR
Intervention: High-dose statin monotherapy
Number of subjects: 1393
Study 21247520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination treatment
Number of subjects: 1393
Study 21247520 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose combination treatment
Number of subjects: 1393
Study 21247520 — intervention group
Group type: COMPARATOR
Intervention: Corresponding-dose statins
Number of subjects: 1393
Study 18423042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodilatation with corticosteroids
Number of subjects: 76
Study 18423042 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 76
Study 17495988 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cognitive therapy for 12 weeks (mean of 5.9 sessions during 12 weeks and 2.0 sessions thereafter)
Number of subjects: 58
Study 17495988 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cognitive therapy for 12 weeks
Number of subjects: 58
Study 17495988 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58
Study 12920367 — intervention group
Group type: EXPERIMENTAL
Intervention: Daivobet (calcipotriol 50 micro g/g, betamethasone dipropionate 0.5 mg/g)
Number of subjects: 45
Study 12920367 — intervention group
Group type: COMPARATOR
Intervention: Diproson (betamethasone dipropionate 0.05 mg/g)
Number of subjects: 45
Study 12920367 — intervention group
Group type: EXPERIMENTAL
Intervention: Daivobet and its vehicle
Number of subjects: 45
Study 12920367 — intervention group
Group type: COMPARATOR
Intervention: Diproson and its vehicle
Number of subjects: 45
Study 10618556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 10400
Study 10618556 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 10400
Study 9373470 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser retinopexy (2 rows of 360 degrees) applied 3-6 weeks prior to silicone oil removal
Number of subjects: 31
Study 9373470 — intervention group
Group type: COMPARATOR
Intervention: Control group (removal of silicone oil without argon laser retinopexy)
Number of subjects: 31
Study 8376687 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 2569
Study 8376687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2569
Study 3519092 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg acebutolol once daily for 12 weeks
Number of subjects: 20
Study 3519092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29428986 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Literacy and ESL Curriculum with CVD specific content
Number of subjects: 155
Study 29428986 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESL curriculum
Number of subjects: 155
Study 25700181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube feeding
Number of subjects: 35
Study 25700181 — intervention group
Group type: COMPARATOR
Intervention: Nil-by-mouth
Number of subjects: 35
Study 25700181 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 24591821 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance and balance training under the guidance of a physiotherapist for 6 months, then facility-guided maintenance training for 6 months
Number of subjects: 300
Study 24591821 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 22717195 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplugged intervention
Number of subjects: 1874
Study 22717195 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1874
Study 20639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger group (n = 8) trained with maximal-effort jump squats with 0%-30% 1RM, three times per week for 10 weeks.
Number of subjects: 24
Study 20639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaker group (n = 8) trained with maximal-effort jump squats with 0%-30% 1RM, three times per week for 10 weeks.
Number of subjects: 24
Study 20639724 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8) with no training intervention.
Number of subjects: 24
Study 18391850 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music designed to increase vitality and improve heart rate variability (HRV) for 20 minutes
Number of subjects: 47
Study 18391850 — intervention group
Group type: COMPARATOR
Intervention: Resting for 20 minutes
Number of subjects: 47
Study 15822738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (botulinic toxin type A)
Number of subjects: 10
Study 15822738 — intervention group
Group type: EXPERIMENTAL
Intervention: Amithryptiline (50 mg/day)
Number of subjects: 10
Study 15822738 — intervention group
Group type: EXPERIMENTAL
Intervention: Amithryptiline (reduced dosage) combined with Dysport
Number of subjects: 10
Study 15822738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 10
Study 12032787 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg every 24 hours (once-daily regimen)
Number of subjects: 41
Study 12032787 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/kg every 12 hours (twice-daily regimen)
Number of subjects: 41
Study 10354195 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate red wine consumption (50 g per day of alcohol)
Number of subjects: 5
Study 10354195 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption (control)
Number of subjects: 5
Study 8933894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS) 4 mg administered via inhalation chamber 30 minutes prior to exercise
Number of subjects: 13
Study 8933894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS) 4 mg every 8 hours during four weeks plus 4 mg of NS 30 minutes before exercise
Number of subjects: 13
Study 8933894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg prior to exercise)
Number of subjects: 13
Study 6407714 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg vitamin E (DL‐alpha‐tocopherol acetate) intramuscularly after birth (day 0) and on days 1, 2, and 3
Number of subjects: 44
Study 6407714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 44
Study 6407714 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 44
Study 30747897 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy combined with chemotherapy (docetaxel)
Number of subjects: 0
Study 30747897 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy combined with abiraterone
Number of subjects: 0
Study 30477839 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day saffron for 8 weeks
Number of subjects: 54
Study 30477839 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 8 weeks
Number of subjects: 54
Study 26065721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic patients
Number of subjects: 72
Study 26065721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic patients with normal BMI
Number of subjects: 72
Study 26065721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic obese patients
Number of subjects: 72
Study 26065721 — intervention group
Group type: COMPARATOR
Intervention: Non-sarcopenic patients
Number of subjects: 72
Study 24619599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM) treatment
Number of subjects: 482
Study 24619599 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 482
Study 22801094 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine (3.75 µg HA/AS03A or 1.9 µg HA/AS03B)
Number of subjects: 322
Study 22801094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted 15 µg HA vaccine
Number of subjects: 322
Study 22801094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted 7.5 µg HA vaccine
Number of subjects: 322
Study 22801094 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines except nonadjuvanted 7.5 µg HA vaccine
Number of subjects: 322
Study 22801094 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccines
Number of subjects: 322
Study 19847482 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-Lipiodol emulsion (group I)
Number of subjects: 20
Study 19847482 — intervention group
Group type: COMPARATOR
Intervention: DC Beads loaded with doxorubicin (group II)
Number of subjects: 20
Study 16904254 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restoration
Number of subjects: 52
Study 15738746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 200 mg/d (BID)
Number of subjects: 341
Study 15738746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 400 mg/d (BID)
Number of subjects: 341
Study 15738746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d (TID)
Number of subjects: 341
Study 15738746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 15738746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (all dosages)
Number of subjects: 341
Study 11954670 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic biking using a wheelchair bicycle in a recreation therapy protocol
Number of subjects: 0
Study 11954670 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic biking
Number of subjects: 0
Study 10454438 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week high potassium diet (80 mmol/24 h)
Number of subjects: 58
Study 10454438 — intervention group
Group type: COMPARATOR
Intervention: Usual diet control group
Number of subjects: 58
Study 8851001 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers occupationally exposed to organic solvents
Number of subjects: 139
Study 8851001 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers occupationally exposed to organic solvents
Number of subjects: 139
Study 8851001 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 139
Study 2181674 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 233
Study 2181674 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 233
Study 393383 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg/week of 5-fluorouracil by oral route
Number of subjects: 57
Study 393383 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg/week of 5-fluorouracil by iv route
Number of subjects: 57
Study 30606886 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane for 5 years
Number of subjects: 3159
Study 30606886 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment of tamoxifen followed by exemestane for 5 years
Number of subjects: 3159
Study 28893875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg zoledronate
Number of subjects: 160
Study 28893875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg zoledronate
Number of subjects: 160
Study 28893875 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zoledronate
Number of subjects: 160
Study 28893875 — intervention group
Group type: COMPARATOR
Intervention: zoledronate (1-5 mg)
Number of subjects: 160